US7358059B2 - Simultaneous quantification of PIG-A associated proteins in red cells, platelets and leukocyte subsets using a single measurement - Google Patents
Simultaneous quantification of PIG-A associated proteins in red cells, platelets and leukocyte subsets using a single measurement Download PDFInfo
- Publication number
- US7358059B2 US7358059B2 US10/338,034 US33803403A US7358059B2 US 7358059 B2 US7358059 B2 US 7358059B2 US 33803403 A US33803403 A US 33803403A US 7358059 B2 US7358059 B2 US 7358059B2
- Authority
- US
- United States
- Prior art keywords
- expression
- neutrophils
- monocytes
- analyzed
- lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/973—Simultaneous determination of more than one analyte
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
Definitions
- the present invention relates generally to a procedure for the simultaneous quantification of at least two different phosphatidyl-inositol glycan complementation class A (PIG-A) associated proteins in red cells, platelets and major leukocyte subsets (including lymphocytes, monocytes, neutrophils and eosinphils) present in blood, using a single measurement.
- PAG-A phosphatidyl-inositol glycan complementation class A
- the present invention allows for testing of both normal and pathological samples obtained ex vivo or in vivo, including stored or treated samples.
- Monoclonal antibodies specific to particular proteins associated with PIG-A are used.
- the following monoclonal antibodies known in the art can be used to practice the present invention: Anti-CD14, Anti-CD16, Anti-CD24, Anti-CD41, Anti-CD42, Anti-CD45, Anti-CD48, Anti-CD52, Anti-CD55, Anti-CD58, Anti-CD59, Anti-CD61, Anti-CD64, Anti-CD66bce, Anti-CD73, Anti-CD 87, Anti-CD90, Anti-CD108, Anti-CD109, and Anti-CD157.
- a common characteristic of these monoclonal antibodies is their ability to identify peripheral blood subtypes of cells, such as CD41, CD42, CD45, CD61, and CD64, or that they are PIG-A anchored surface proteins.
- PIG-A anchored surface proteins One source for further information in this regard is Immunobiology: The immune system in health and disease , Appendix I, Janeway C. A., Travers P., Walport M., and Capra J. D. (Eds.), Elserior Science Ltd./Garland Publishing, 1999.
- the monoclonal antibodies are chemically coupled to fluorochromes to permit visualization and quantification of different cell types. This coupling does not alter the binding capacity of the antibodies.
- the fluorochrome-labeled antibody When activated by illumination with light of a particular wavelength, the fluorochrome-labeled antibody adsorbs the light energy, inducing a state of excitability followed by emission of light at a characteristic color.
- any compatible combination of fluorochromes can be used as well as any monoclonal antibody within each cluster of differentiation.
- FL1 fluorescein isothiocyanate FITC
- PE phycoerythrin
- PerCP peridin chlorophyll protein
- APC allophycocyanin
- fluorochromes or fluorochrome tandems is the combination of FITC, PE, PerCP and APC-Cyanin7 (Cy7).
- FITC fluorescence Activated Cell
- PE PerCP-Cy5 and APC
- ITC PE, PE-Cy5 and APC
- FITC fluorescence Activated Cell
- PE-Cy PE-texas red
- FITC PE, PE-Cy5 and APC-Cy7.
- the fluorochromes employed in the practice of the present invention are commercially available and understood by those of skill in the art.
- a blood sample is incubated with a mixture of monoclonal antibodies and fluorochromes as follows:
- Anti-CD45 Monoclonal Antibody Number Antibody Fluorochrome 1 Anti-CD45 1 2 Anti-CD61 or 1 Anti-CD41 or Anti-CD42 3 Anti-CD64 2 4 Anti-CD55 3 5 Anti-CD59 4
- Monoclonal antibodies 1-3 allow for identification of red cells, platelets, and the major leukocyte subsets in the blood sample.
- Monoclonal antibodies 4 and 5 allow for quantification of each cell subset for the two different PIG-A associated proteins.
- a patient's blood sample may be collected in a glass or plastic tube containing an anticoagulant such as EDTA, heparin or ACD. Any reasonable volume may be used, such as from 1-200 ⁇ l, the concentration of other reagents to be determined based on the volume of the sample and the saturation conditions of the reagents.
- the sample should be used as soon as possible, if stored it may be placed at room temperature (approximately 22° C.) or refrigerated (approximately 4° C.).
- the antibody coupled to fluorochrome reagents can be purchased from a number of commercial sources. Upon addition of this reagent to the blood sample, incubation of the sample follows for approximately 30 minutes at room temperature, or for approximately 30-60 minutes under refrigeration.
- Fluorescence is measured in a flow cytometer.
- the scale used for each measured parameter is typically a 4-logarithmic decades scale. Results are expressed in relative linear units scaled from 0 to 10 4 .
- the techniques and equipment utilized for fluorescence as well as light scattering measurements are well established in the art.
- the resultant information can De stored in digital format, making it easy to analyze several parameters for a single cell through the use of specialized software programs.
- red cells are identified as being CD45 ⁇ and CD61 ⁇ (or CD41 ⁇ or CD42 ⁇ ) and displaying a high forward scatter (FSC) and sideward light scatter (SSC).
- Platelets show low FSC and SSC values and they are CD61+ (or CD41+ or CD42+).
- Leukocytes appear as high FSC and CD45+: from them lymphocytes show higher CD45+ values and they are CD64 ⁇ ; monocytes are CD64++ at very high levels, they show intermediate SSC characteristics as compared to neutrophils and eosinophils these latter cells being CD64+ with high SSC and CD64 ⁇ with very high SSC values, respectively.
- a blood sample is incubated with a mixture of monoclonal antibodies and fluorochromes as follows:
- Anti-CD45 Monoclonal Antibody Number Antibody Fluorochrome 1 Anti-CD45 2 2 Anti-CD61 or 1 Anti-CD41 or Anti-CD42 3 Anti-CD64 1 4 Anti-CD55 3 5 Anti-CD59 4
- CD55 and/or CD59 may be replaced by other antigens, including, but not limited to, CD14, CD16, CD24, CD48, CD52, CD58, CD66bce, CD73, CD87, CD90, CD108, CD109, and CD157.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A single measurement can quantify phosphatidyl-inositol glycan complementation class A (PIG-A) associated proteins in red cells, platelets and the major leukocyte subsets present in blood (lymphocytes, monocytes, neutrophils and eosinophils). The single measurement relies on flow cytometry to simultaneously evaluate intensity of fluorochrome emissions and light scattering properties.
Description
The present invention relates generally to a procedure for the simultaneous quantification of at least two different phosphatidyl-inositol glycan complementation class A (PIG-A) associated proteins in red cells, platelets and major leukocyte subsets (including lymphocytes, monocytes, neutrophils and eosinphils) present in blood, using a single measurement.
The present invention may be understood more readily by reference to the following detailed description of particular embodiments of the invention and specific examples. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
The present invention allows for testing of both normal and pathological samples obtained ex vivo or in vivo, including stored or treated samples. Monoclonal antibodies specific to particular proteins associated with PIG-A are used. For example, the following monoclonal antibodies known in the art can be used to practice the present invention: Anti-CD14, Anti-CD16, Anti-CD24, Anti-CD41, Anti-CD42, Anti-CD45, Anti-CD48, Anti-CD52, Anti-CD55, Anti-CD58, Anti-CD59, Anti-CD61, Anti-CD64, Anti-CD66bce, Anti-CD73, Anti-CD 87, Anti-CD90, Anti-CD108, Anti-CD109, and Anti-CD157. A common characteristic of these monoclonal antibodies is their ability to identify peripheral blood subtypes of cells, such as CD41, CD42, CD45, CD61, and CD64, or that they are PIG-A anchored surface proteins. One source for further information in this regard is Immunobiology: The immune system in health and disease, Appendix I, Janeway C. A., Travers P., Walport M., and Capra J. D. (Eds.), Elserior Science Ltd./Garland Publishing, 1999.
The monoclonal antibodies are chemically coupled to fluorochromes to permit visualization and quantification of different cell types. This coupling does not alter the binding capacity of the antibodies. When activated by illumination with light of a particular wavelength, the fluorochrome-labeled antibody adsorbs the light energy, inducing a state of excitability followed by emission of light at a characteristic color.
In order to specifically identify antibody binding to cells, any compatible combination of fluorochromes can be used as well as any monoclonal antibody within each cluster of differentiation. For example, FL1 fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridin chlorophyll protein (PerCP) and allophycocyanin (APC). Another example of suitable combinations of fluorochromes or fluorochrome tandems is the combination of FITC, PE, PerCP and APC-Cyanin7 (Cy7). Further examples include: FITC, PE, PerCP-Cy5 and APC; or ITC, PE, PE-Cy5 and APC, or FITC, PE, PE-Cy, PE-texas red; or FITC, PE, PE-Cy5 and APC-Cy7. The fluorochromes employed in the practice of the present invention are commercially available and understood by those of skill in the art.
In a first embodiment of the present invention, a blood sample is incubated with a mixture of monoclonal antibodies and fluorochromes as follows:
| Monoclonal | ||
| Antibody Number | Antibody | Fluorochrome |
| 1 | Anti-CD45 | 1 |
| 2 | Anti-CD61 or | 1 |
| Anti-CD41 or | ||
| Anti-CD42 | ||
| 3 | Anti-CD64 | 2 |
| 4 | Anti-CD55 | 3 |
| 5 | Anti-CD59 | 4 |
The full complement of monoclonal antibodies allows for a complete analysis of the blood sample. Monoclonal antibodies 1-3 allow for identification of red cells, platelets, and the major leukocyte subsets in the blood sample. Monoclonal antibodies 4 and 5 allow for quantification of each cell subset for the two different PIG-A associated proteins.
A patient's blood sample may be collected in a glass or plastic tube containing an anticoagulant such as EDTA, heparin or ACD. Any reasonable volume may be used, such as from 1-200 μl, the concentration of other reagents to be determined based on the volume of the sample and the saturation conditions of the reagents. The sample should be used as soon as possible, if stored it may be placed at room temperature (approximately 22° C.) or refrigerated (approximately 4° C.).
The antibody coupled to fluorochrome reagents can be purchased from a number of commercial sources. Upon addition of this reagent to the blood sample, incubation of the sample follows for approximately 30 minutes at room temperature, or for approximately 30-60 minutes under refrigeration.
Fluorescence is measured in a flow cytometer. The scale used for each measured parameter is typically a 4-logarithmic decades scale. Results are expressed in relative linear units scaled from 0 to 104. The techniques and equipment utilized for fluorescence as well as light scattering measurements are well established in the art. The resultant information can De stored in digital format, making it easy to analyze several parameters for a single cell through the use of specialized software programs.
The results of the data indicate which types of cells are present in a sample based on particular characteristics. For example, red cells are identified as being CD45− and CD61− (or CD41− or CD42−) and displaying a high forward scatter (FSC) and sideward light scatter (SSC). Platelets show low FSC and SSC values and they are CD61+ (or CD41+ or CD42+). Leukocytes appear as high FSC and CD45+: from them lymphocytes show higher CD45+ values and they are CD64−; monocytes are CD64++ at very high levels, they show intermediate SSC characteristics as compared to neutrophils and eosinophils these latter cells being CD64+ with high SSC and CD64− with very high SSC values, respectively. Once these cell populations are identified, expression of PIG-A associated proteins is evaluated on each subset. The evaluation is based on both the presence or absence and the mean fluorescence intensity of unimodal or multimodal populations.
In a second embodiment of the present invention, a blood sample is incubated with a mixture of monoclonal antibodies and fluorochromes as follows:
| Monoclonal | ||
| Antibody Number | Antibody | Fluorochrome |
| 1 | Anti-CD45 | 2 |
| 2 | Anti-CD61 or | 1 |
| Anti-CD41 or | ||
| Anti-CD42 | ||
| 3 | Anti-CD64 | 1 |
| 4 | Anti-CD55 | 3 |
| 5 | Anti-CD59 | 4 |
In further embodiments of the present invention, all potential combinations of antibodies may be used. For example, CD55 and/or CD59 may be replaced by other antigens, including, but not limited to, CD14, CD16, CD24, CD48, CD52, CD58, CD66bce, CD73, CD87, CD90, CD108, CD109, and CD157.
It is also possible to follow the teaching of the present invention but to rely on only two or three different fluorochromes. This procedure may be used for analysis of a single PIG-A protein, or when quantification and analysis of a reduced number of blood cell types within a sample is necessary.
Claims (18)
1. A method for the simultaneous quantification of the levels of expression of the CD55 and CD59 phosphatidyl-inositol glycan complementation class A (PIG-A) anchored cell membranes proteins in red cells, platelets, lymphocytes, monocytes, neutrophils and eosinophils present in a blood sample aliquot, comprising the steps of:
incubating the blood sample with a mixture of fluorochrome-conjugated monoclonal antibodies directed against the CD45, CD61, CD55 and CD59 cell surface proteins;
measuring the intensity of the fluorescence emissions of the fluorochrome-conjugated monoclonal antibodies bound to the cells contained in said incubated blood sample;
measuring the light scattering properties of the bound cells contained in said incubated blood sample;
identifying the different subsets of red cells, platelets, lymphocytes, monocytes, neutrophils and eosinophils present in said blood sample based on their differential expression of CD45 and CD61 and different quantities of both forward (FSC) and sideward (SSC) light scattering properties, and;
simultaneously quantifying the expression of CD55 and CD59 for each of said blood cell subsets,
wherein the CD45 and CD61 monoclonal antibodies are conjugated to the same fluorochrome and the CD55 and CD59 monoclonal antibodies are conjugated to a second and a third different fluorochromes.
2. The method according to claim 1 , wherein said fluorochromes or fluorochrome tandems are selected from the groups consisting of fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin Chlorophyl protein (PerCP), PE-cyanin5 (PE Cy5), PE-Cyanin7 (PE Cy7), allophycocyanin (APC), PE-Texas red and APC-Cy7.
3. The method of claim 1 , wherein the monoclonal antibodies used to identify and distinguish between red cells, platelets, lymphocytes, monocytes, neutrophils and eosinophils include a mixture of CD61, CD45 and CD64 monoclonal antibodies.
4. The method according to claim 1 wherein the monoclonal antibodies used to identify and distinguish between red cells, platelets, lymphocytes, monocytes, neutrophils and eosinophils include a mixture of CD41, CD45 and CD64 monoclonal antibodies.
5. The method according to claim 1 wherein the monoclonal antibodies used to identify and distinguish between red cells, platelets, lymphocytes, monocytes, neutrophils and eosinophils include a mixture of CD42, CD45 and CD64 monoclonal antibodies.
6. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD14 on monocytes is also analyzed.
7. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD24 on neutrophils and lymphocytes is also analyzed.
8. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD16 on neutrophils is also analyzed.
9. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD66bce on neutrophils is also analyzed.
10. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD48 on lymphocytes and monocytes is also analyzed.
11. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD52 on lymphocytes, monocytes, neutrophils and eosinophils is also analyzed.
12. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD58 on lymphocytes, monocytes, neutrophils and eosinophils is also analyzed.
13. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD73 on lymphocytes, is also analyzed.
14. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD87 on monocytes, and neutrophils is also analyzed.
15. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD90 on lymphocytes, is also analyzed.
16. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD 108 on lymphocytes, monocytes, neutrophils and eosinophils is also analyzed.
17. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD 109 on monocytes, neutrophils and eosinophils is also analyzed.
18. The method according to claim 1 wherein, in addition to the expression of CD55 and CD59 on said cell subsets, the expression of CD 157 on monocytes, and neutrophils is also analyzed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/338,034 US7358059B2 (en) | 2002-01-09 | 2003-01-08 | Simultaneous quantification of PIG-A associated proteins in red cells, platelets and leukocyte subsets using a single measurement |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34629702P | 2002-01-09 | 2002-01-09 | |
| US10/338,034 US7358059B2 (en) | 2002-01-09 | 2003-01-08 | Simultaneous quantification of PIG-A associated proteins in red cells, platelets and leukocyte subsets using a single measurement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20030138851A1 US20030138851A1 (en) | 2003-07-24 |
| US7358059B2 true US7358059B2 (en) | 2008-04-15 |
Family
ID=26990999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/338,034 Expired - Fee Related US7358059B2 (en) | 2002-01-09 | 2003-01-08 | Simultaneous quantification of PIG-A associated proteins in red cells, platelets and leukocyte subsets using a single measurement |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US7358059B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070274919A1 (en) * | 2006-05-25 | 2007-11-29 | Litron Laboratories, Ltd. | Method for measuring in vivo mutation frequency at an endogenous gene locus |
| US20090311706A1 (en) * | 2008-06-12 | 2009-12-17 | Litron Laboratories, Ltd. | Quantitative analysis of in vivo mutation at the pig-a locus |
| WO2011070059A1 (en) | 2009-12-11 | 2011-06-16 | Ge Healthcare Uk Limited | Methods of detecting dna damage |
| US9133505B2 (en) | 2010-11-24 | 2015-09-15 | Litron Laboratories, Ltd. | Rapid in vivo gene mutation assay based on the Pig-A gene |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2215219A4 (en) * | 2007-10-29 | 2011-04-13 | Beckman Coulter Inc | Method for a rapid antibody-based analysis of platelet populations |
| CN114441419B (en) * | 2022-01-29 | 2022-11-22 | 杭州翔宇医学检验实验室有限公司 | Flow type gate looping method and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6287791B1 (en) * | 1992-01-22 | 2001-09-11 | Becton Dickinson And Company | Multidimensional cell differential analysis |
-
2003
- 2003-01-08 US US10/338,034 patent/US7358059B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6287791B1 (en) * | 1992-01-22 | 2001-09-11 | Becton Dickinson And Company | Multidimensional cell differential analysis |
Non-Patent Citations (2)
| Title |
|---|
| Griscelli-Bennaceur et al., Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria: Search for a pathogenic Link, Blood 85 (5): 1354-1363 (Mar. 1, 1995). * |
| Richards et al., Application of Flow Cytometry in the Diagnosis of Paroxysmal Nocturnal Hemoglobinuria, Cytometry 42: 223-233 (2000). * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070274919A1 (en) * | 2006-05-25 | 2007-11-29 | Litron Laboratories, Ltd. | Method for measuring in vivo mutation frequency at an endogenous gene locus |
| US7824874B2 (en) * | 2006-05-25 | 2010-11-02 | Litron Laboratories, Ltd. | Method for measuring in vivo mutation frequency at an endogenous gene locus |
| US20110027793A1 (en) * | 2006-05-25 | 2011-02-03 | Litron Laboratories, Ltd. | Kit for measuring in vivo mutation frequency at an endogenous gene locus |
| US8062860B2 (en) * | 2006-05-25 | 2011-11-22 | Litron Laboratories, Ltd. | Kit for measuring in vivo mutation frequency at an endogenous gene locus |
| US20090311706A1 (en) * | 2008-06-12 | 2009-12-17 | Litron Laboratories, Ltd. | Quantitative analysis of in vivo mutation at the pig-a locus |
| US8187826B2 (en) * | 2008-06-12 | 2012-05-29 | Litron Laboratories, Ltd. | Quantitative analysis of in vivo mutation at the Pig-A locus |
| WO2011070059A1 (en) | 2009-12-11 | 2011-06-16 | Ge Healthcare Uk Limited | Methods of detecting dna damage |
| US9133505B2 (en) | 2010-11-24 | 2015-09-15 | Litron Laboratories, Ltd. | Rapid in vivo gene mutation assay based on the Pig-A gene |
Also Published As
| Publication number | Publication date |
|---|---|
| US20030138851A1 (en) | 2003-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6900023B1 (en) | Method for classifying and counting leukocytes | |
| US5776709A (en) | Method for preparation and analysis of leukocytes in whole blood | |
| EP0347039B1 (en) | Method for discriminating between intact and damaged cells in a sample | |
| Fujimoto et al. | Flow cytometric method for enumeration and classification of reactive immature granulocyte populations | |
| Stelzer et al. | CD45 gating for routine flow cytometric analysis of human bone marrow specimens | |
| DK2743698T3 (en) | METHODS, REAGENTS, AND KITS FOR FLOW CYTOMETRIC IMMUNPHONE TYPE DETERMINATION | |
| US5153117A (en) | Fetal cell recovery method | |
| EP1770387B1 (en) | Generation of the flow cytometry data files with a potentially infinite number of dimensions derived from the fusion of a group of separate flow cytometry data files and their multidimensional reconstruction with both actually measured and estimated flow cytometry data | |
| JPH0627017A (en) | Multidimensional cell discriminating analyzing method | |
| Weiss | Application of flow cytometric techniques to veterinary clinical hematology | |
| US7332295B2 (en) | Multidimensional leukocyte differential analysis | |
| US20120231473A1 (en) | Flow cytometry method through the control of fluorescence intensities | |
| US7507548B2 (en) | Multidimensional detection of aberrant phenotypes in neoplastic cells to be used to monitor minimal disease levels using flow cytometry measurements | |
| Hernández‐Campo et al. | Comparative analysis of different flow cytometry‐based immunophenotypic methods for the analysis of CD59 and CD55 expression on major peripheral blood cell subsets | |
| US7358059B2 (en) | Simultaneous quantification of PIG-A associated proteins in red cells, platelets and leukocyte subsets using a single measurement | |
| EP0559208B1 (en) | Method for preparation and analysis of leukocytes in whole blood utilizing flow cytometry | |
| Olteanu et al. | Differential usefulness of various markers in the flow cytometric detection of paroxysmal nocturnal hemoglobinuria in blood and bone marrow | |
| Gilman-Sachs | Flow cytometry | |
| US20090246805A1 (en) | Method for classifying and counting basophils | |
| Nebe et al. | Flow Cytometric Analysis of GPI-deficient Cells for the Diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH)/Durchflußzytometrische Analyse GPI-defizienter Zellen zur Diagnose der paroxysmalen nächtlichen Hämoglobinurie (PNH) | |
| Scheffold et al. | 1 Phenotyping and Separation of Leukocyte Populations Based on Affinity Labelling | |
| JP4768706B2 (en) | A multidimensional detection method for abnormal phenotypes in neoplastic cells used to monitor minimal disease levels using fluid cytometry | |
| US20240248091A1 (en) | Means and methods for the diagnosis, classification and/or monitoring of pediatric tumors | |
| Richards | Paroxysmal Nocturnal Hemoglobinuria (PNH) Analysis | |
| EP0685071A1 (en) | Method for absolute counting of rare cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: UNIVERSIDAD DE SALAMANCA, SPAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DE MATOS, ALBERTO ORFAO;REEL/FRAME:013894/0785 Effective date: 20030131 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20160415 |